Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
SUVEN LIFE SCIENCES ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUVEN LIFE SCIENCES Mar-23 |
ADCOCK INGRAM Jun-14 |
SUVEN LIFE SCIENCES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 94 | 331 | - | |
Low | Rs | 45 | 238 | - | |
Sales per share (Unadj.) | Rs | 0.6 | 98.3 | - | |
Earnings per share (Unadj.) | Rs | -5.4 | -24.8 | - | |
Cash flow per share (Unadj.) | Rs | -5.1 | -20.5 | - | |
Dividends per share (Unadj.) | Rs | 0 | 0 | - | |
Avg Dividend yield | % | 0 | 0 | - | |
Book value per share (Unadj.) | Rs | 17.2 | 77.2 | - | |
Shares outstanding (eoy) | m | 218.07 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 111.8 | 2.9 | 3,862.5% | |
Avg P/E ratio | x | -12.8 | -11.5 | 111.4% | |
P/CF ratio (eoy) | x | -13.5 | -13.9 | 97.7% | |
Price / Book Value ratio | x | 4.0 | 3.7 | 109.4% | |
Dividend payout | % | 0 | 0 | - | |
Avg Mkt Cap | Rs m | 15,131 | 48,025 | 31.5% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 186 | 3,014 | 6.2% | |
Avg. sales/employee | Rs Th | 0 | 3,866.4 | - | |
Avg. wages/employee | Rs Th | 0 | 702.1 | - | |
Avg. net profit/employee | Rs Th | 0 | -974.2 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 135 | 16,598 | 0.8% | |
Other income | Rs m | 84 | 116 | 72.7% | |
Total revenues | Rs m | 220 | 16,715 | 1.3% | |
Gross profit | Rs m | -1,196 | -2,876 | 41.6% | |
Depreciation | Rs m | 65 | 716 | 9.1% | |
Interest | Rs m | 5 | 450 | 1.2% | |
Profit before tax | Rs m | -1,183 | -3,926 | 30.1% | |
Minority Interest | Rs m | 0 | -11 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 0 | 245 | 0.0% | |
Profit after tax | Rs m | -1,183 | -4,182 | 28.3% | |
Gross profit margin | % | -883.6 | -17.3 | 5,099.1% | |
Effective tax rate | % | 0 | -6.2 | 0.0% | |
Net profit margin | % | -873.5 | -25.2 | 3,466.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 3,455 | 12,157 | 28.4% | |
Current liabilities | Rs m | 1,050 | 6,840 | 15.4% | |
Net working cap to sales | % | 1,776.0 | 32.0 | 5,544.4% | |
Current ratio | x | 3.3 | 1.8 | 185.1% | |
Inventory Days | Days | 3,948 | 111 | 3,560.0% | |
Debtors Days | Days | 218 | 124 | 175.6% | |
Net fixed assets | Rs m | 1,373 | 7,086 | 19.4% | |
Share capital | Rs m | 218 | 77 | 283.0% | |
Net worth | Rs m | 3,753 | 13,028 | 28.8% | |
Long term debt | Rs m | 0 | 4,578 | 0.0% | |
Total assets | Rs m | 4,828 | 24,611 | 19.6% | |
Interest coverage | x | -218.8 | -7.7 | 2,830.1% | |
Debt to equity ratio | x | 0 | 0.4 | 0.0% | |
Sales to assets ratio | x | 0 | 0.7 | 4.2% | |
Return on assets | % | -24.4 | -15.2 | 160.8% | |
Return on equity | % | -31.5 | -32.1 | 98.2% | |
Return on capital | % | -31.4 | -19.8 | 158.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -1,031 | 1,417 | -72.8% | |
From Investments | Rs m | -2,606 | -435 | 599.2% | |
From Financial Activity | Rs m | 3,955 | 4,155 | 95.2% | |
Net Cashflow | Rs m | 317 | 5,137 | 6.2% |
Compare SUVEN LIFE SCIENCES With: MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Compare SUVEN LIFE SCIENCES With: GLENMARK LIFE SCIENCES BAL PHARMA AARTI DRUGS INDOCO REMEDIES NATCO PHARMA
Indian share markets continued the momentum as the session progressed and ended on firm footing.